| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total operating expenses | 30,392 | 28,980 | 27,292 | 27,810 |
| Loss from operations | -4,093 | -1,637 | 3,154 | -4,458 |
| Loss on debt extinguishment | -11,339 | - | - | - |
| Other expense, net | -2,063 | -744 | -519 | -390 |
| Net loss | -17,495 | -2,381 | 2,635 | -4,848 |
| Unrealized gain (loss) on short-term investments | 1 | -2 | -12 | 48 |
| Comprehensive loss | -17,494 | -2,383 | 2,623 | -4,800 |
| Earnings per share, basic | -0.1 | -0.02 | 0.02 | -0.03 |
| Earnings per share, diluted | -0.1 | -0.02 | 0.01 | -0.03 |
| Weighted average common shares outstanding, basic | 170,348,000 | 154,020,000 | 153,490,000 | 152,830,000 |
| Weighted average common shares outstanding, diluted | 170,348,000 | 154,020,000 | 196,921,000 | 152,830,000 |
HERON THERAPEUTICS, INC. DE (HRTX)
HERON THERAPEUTICS, INC. DE (HRTX)